Benefit of interferon-α(2b) in a patient with unresectable hepatoma and chronic infection with hepatitis C virus

European Journal of Gastroenterology and Hepatology

Volumn 12, Issue 2, 2000, Pages 251-253

  Locker, Gottfried J ^a   Mader, Robert M ^a   Steiner, Birgit ^a   Wenzl, Etienne ^a   Zielinski, Christoph C ^a   Steger, Guenther G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Hepatocellular carcinoma; Interferon alpha; Viral hepatitis

Indexed keywords

HEPATITIS C ANTIBODY; LIVER ENZYME; RECOMBINANT ALPHA2B INTERFERON; TUMOR MARKER; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT;

AGED; ARTICLE; CANCER SURGERY; CASE REPORT; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SERODIAGNOSIS; TREATMENT CONTRAINDICATION; TUMOR REGRESSION; FATALITY; LIVER TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FATAL OUTCOME; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; LIVER NEOPLASMS;

EID: 0033621865     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200012020-00021     Document Type: Article

References (15)

1. 1 Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997; 8:117-136.
2. 2 Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693-699.
3. 3 Pardo M, Marriot E, Moliner MC, Quiroga JA, Carreno V. Risks and benefits of interferon-alpha in the treatment of hepatitis. Drug Safety 1995; 13:304-316.
4. 4 Schalm SW, Fattovich G, Brouwer JT. Therapy of hepatitis C: patients with cirrhosis. Hepatology 1997; 26(suppl 1):S128-S132.
5. 5 Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 1997; 27:201-205.
6. 6 Mazella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24:141-147.
7. 7 Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346:1051-1055.
8. 8 Stremmel W, Schwarzendrube J, Niederau C, Strohmeyer G. Epidemiology, clinical course and treatment of chronic viral hepatitis. Hepatogastroenterology 1991; 38:22-28.
9. 9 Sahara Al, Hunt CM, Hamilton JD. Hepatitis C. Ann Intern Med 1996; 125:658-668.
10. 10 Dinarello CA, Mier JW. Lymphokines. N Engl J Med 1987; 317:940-945.
11. 11 Dunk AA, Ikeda T, Pignatelli M, Thomas HC. Human lymphoblastoid interferon: in vitro and in vivo studies in hepatocellular carcinoma. J Hepatol 1986; 2:419-429.
12. 12 The Gastrointestinal Tumor Study Group. A prospective trial of recombinant human interferon alpha 2b in previously untreated patients with hepatocellular carcinoma. Cancer 1990; 66:135-139.
13. 13 Sachs E, Di Bisceglie AM, Dushieko GM, Song E, Lyons SF, Schoub BD, et al. Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study. Br J Cancer 1985; 52:105-109.
14. 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Br J Cancer 1989; 60:928-933.
15. 15 Lai CL, Lau JY, Wu PC, Ngan H, Chung HT, Mitchell SJ, et al. Recombinant interferon-α in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993; 17:389-395.